| Item type |
itemtype_ver1(1) |
| 公開日 |
2024-08-29 |
| タイトル |
|
|
タイトル |
Thyroid autoantibodies at baseline predict longer survival in non-small cell lung cancer patients treated with anti-programmed cell death-1 blockade: a prospective study |
|
言語 |
en |
| 著者 |
Okuji, Takayuki
Iwama, Shintaro
Kobayashi, Tomoko
Yasuda, Yoshinori
Ito, Masaaki
Yamagami, Ayana
Ando, Masahiko
Hase, Tetsunari
Shibata, Hirofumi
Hatta, Takahiro
Zhou, Xin
Onoue, Takeshi
Kawaguchi, Yohei
Miyata, Takashi
Sugiyama, Mariko
Hagiwara, Daisuke
Suga, Hidetaka
Banno, Ryoichi
Ando, Yuichi
Hashimoto, Naozumi
Arima, Hiroshi
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利 |
|
|
言語 |
en |
|
権利情報Resource |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
|
権利情報 |
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
autoimmunity |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
lung neoplasms |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
biomarkers |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
thyroid |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
programmed cell death-1 (PD-1) |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
The presence of anti-thyroid antibodies (ATAs) is a biomarker for the development of thyroid dysfunction induced by anti-programmed cell death-1 antibodies (PD-1-Abs). While patients with thyroid dysfunction reportedly showed better overall survival (OS), it remains unknown if ATAs at baseline can predict OS. Therefore, in this study, we examined the association of ATAs at baseline with OS in non-small cell lung cancer (NSCLC) patients with different levels of programmed cell death-1 ligand 1 (PD-L1) positivity associated with PD-1-Ab treatment efficacy. A total of 81 NSCLC patients treated with PD-1-Abs were evaluated for ATAs at baseline and prospectively for OS. Among the 81 patients, 49 and 32 patients had ≥50% (group A) and <50% (group B) PD-L1 positivity, respectively. Median OS did not differ significantly between patients with (n = 13) and without (n = 36) ATAs at baseline in group A. In contrast, median OS was significantly longer in patients with (n = 10) versus without (n = 22) ATAs at baseline in group B (not reached vs 378 days, respectively; 95% CI, 182 to 574 days, p = 0.049). These findings suggest that the presence of ATAs at baseline is a biomarker to predict better treatment efficacy of PD-1-Abs in NSCLC patients with low PD-L1 positivity, while the difference in OS in those with high PD-L1 positivity may be masked by increased tumor expression of PD-L1. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Nagoya University Graduate School of Medicine, School of Medicine |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
departmental bulletin paper |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| ID登録 |
|
|
ID登録 |
10.18999/nagjms.86.3.452 |
|
ID登録タイプ |
JaLC |
| 関連情報 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/863.html |
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0027-7622 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2186-3326 |
| 書誌情報 |
en : Nagoya Journal of Medical Science
巻 86,
号 3,
p. 452-463,
発行日 2024-08
|
09_Okuji.pdf (785 KB)
.png)
